François-Clément Bidard, MD, PhD, of the Institut Curie and the University of Versailles, discusses phase III study findings on the clinical utility of circulating tumor cell count as a tool to choose between first-line hormone therapy and chemotherapy for estrogen receptor–positive, HER2-negative metastatic breast cancer (Abstract GS3-07).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Charles E. Geyer, MD, of Virginia Commonwealth University, discuss phase III study findings o...
Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse ...
Reshma Jagsi, MD, DPhil, of the University of Michigan, and Rachel A. Freedman, MD, MPH, of Dana-Farber Cancer Institute, discuss the twin challenges of overtreati...
Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of...
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the natural history and novel combinations for HER2-positive disease as well as predictive and prognost...